Drug Profile
NVX 508
Alternative Names: NVX-508Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator NuvOx Pharma
- Class Antianaemics
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Vaso-occlusive crisis
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Vaso-occlusive-crisis in USA
- 02 Jul 2020 NVX 508 is still in preclinical development for Vaso-occlusive-crisis in sickle cell disease in USA (NuvOx Pharma pipeline, July 2020)
- 16 Jul 2018 NuvOx and the University of Pittsburgh withdraws a phase I trial in Vaso-occlusive crisis related to sickle cell anaemia in USA, prior to enrolment (NCT03013426)